Search
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalOn December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … [L28310] Vibegron is the second beta-3 adrenergic agonist approved for the treatment of overactive bladder following [mirabegron], which was approved in 2012.
Categories: Drugs for Urinary Frequency and IncontinenceCyanocobalamin Co-60
go.drugbank.com/drugs/DB09387ApprovedWithdrawnCyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.
Medrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnIt was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. … Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone.
Idebenone
go.drugbank.com/drugs/DB09081ApprovedInvestigationalthe lipid membrane and mitochondria from oxidative damage [A19768]. … It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada.
Categories: Psychostimulants, Agents Used for ADHD and Nootropics, Compounds used in a research, industrial, or household settingPentoxifylline
go.drugbank.com/drugs/DB00806ApprovedInvestigational[A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but … [A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated for
Categories: Drugs for Obstructive Airway Diseases, Compounds used in a research, industrial, or household settingAliskiren
go.drugbank.com/drugs/DB09026ApprovedInvestigationalAliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. … [A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.
Categories: Antihypertensive Agents Indicated for HypertensionBaricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.
Categories: Experimental Unapproved Treatments for COVID-19Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to
Levonorgestrel
go.drugbank.com/drugs/DB00367ApprovedInvestigational[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD.
Categories: Hormonal Contraceptives for Systemic UsePepsin
go.drugbank.com/drugs/DB13198ApprovedWithdrawnStudies on gastric digestion from 1820-1840 led to the discovery of pepsin as the substance which, in the presence of stomach acid, causes nutrients including meat or coagulated egg whites to dissolve. … Pepsin is often used as a replacement enzyme for those with pancreatic insufficiency [L2357].